Other Hematologic Malignancies
Improving responses in multiple myeloma
An established treatment approach for transplant-eligible patients with newly diagnosed multiple myeloma (MM) is induction treatment with bortezomib, lenalidomide and dexamethasone (VRd) followed by autologous stem cell transplantation (ASCT), VRd consolidation, and lenalidomide maintenance. The multinational phase III PERSEUS study compared this schedule to an expanded regimen containing the anti-CD38 antibody daratumumab in addition to induction and consolidation with VRd (D-VRd) as well as lenalidomide maintenance (D-R).